PM Images/DigitalVision via Getty Images
This is my third Outlook Therapeutics (NASDAQ:OTLK) article. As I will discuss, its situation is getting stickier in terms of current liquidity and timing. I am downgrading my Strong Buy rating from 06/2024's "Outlook Therapeutics: Worth A Good Strong Look After CRL"; instead, I am rating
Analyst’s Disclosure:I/we have a beneficial long position in the shares of OTLK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I may buy or sell shares in a company mentioned.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
